NCT02877368

✓ Unanimous Initial: hospital

✓ Unanimous Initial: other

✓ Unanimous Initial: hospital Requery: other — The trial does not specify a distinct location for intervention delivery, potentially involving outpatient or community settings as it involves routine CT scans for sarcopenia and imatinib, which do not require hospitalization.

✓ Unanimous Initial: no Requery: no — The intervention involves computed tomography (CT) scans for diagnostic/screening purposes, which falls under the screening category.

✓ Unanimous Initial: yes Requery: no — This is an observational study using computed tomography imaging for measurement purposes, which falls under the screening/diagnostic category rather than being a therapeutic intervention. Thinking: no — The CT scan is a screening/assessment tool used to evaluate sarcopenia, fitting the screening category.

✓ Unanimous Initial: yes Requery: yes — The use of computed tomography (CT) scans as a non-invasive imaging technique for evaluating sarcopenia does not fit into the specified categories and aligns with environmental modifications. Thinking: no — The only intervention is computed tomography imaging, which falls under the screening/diagnostic category.

✓ Unanimous Initial: yes

✓ Unanimous Initial: no Requery: yes — The secondary outcome measures imatinib-induced toxicities including specific symptoms like nausea, diarrhea, vomiting, asthenia, muscle cramps, and arthralgia graded by NCI Common Toxicity Criteria.

✓ Unanimous Initial: yes Requery: yes — The secondary outcomes explicitly list symptoms such as nausea, pruritus, diarrhea, vomiting, asthenia, and muscle cramps, which are direct assessments of symptoms.

✓ Unanimous Initial: yes Requery: no — The outcomes (sarcopenia and imatinib-induced toxicities) fit into symptom/medical categories rather than the specified other categories like caregiver outcomes or survival.

✓ Unanimous Initial: yes Requery: no — All outcomes (sarcopenia assessment and imatinib-induced toxicities) are clinical/physiological measurements that fall under symptom/adverse event categories rather than other palliative care outcomes. Thinking: yes — Outcomes measure sarcopenia (muscle mass index) and drug toxicities, not symptom relief, quality of life, dignity, or cost.

✓ Unanimous Initial: no Requery: yes — The trial includes an assessment of sarcopenia, which does not fall under symptom/QoL/dignity/cost categories. Thinking: yes — Primary outcome is change in sarcopenia (muscle mass), which is a physiological/body‐composition metric not covered by symptom, QoL, dignity, or cost categories.